MindRank AI to Showcase AI-Driven Drug Discovery Platform and Clinical Pipeline at BIO-Europe Spring 2025

March 17-19, 2025"MindRank"Will attend"Italy, Milan"Held in the European Biotechnology Field「BIO-Europe Spring」and delivered a keynote speech, discussing cutting-edge industry trends with scientific leaders and industry pioneers in the global biopharmaceutical field, and seeking new opportunities for strategic cooperation.

For more information, please visit:

https://informaconnect.com/bioeurope-spring/

BIO-Europe Conference is one of the premier platforms for companies in Europe's top innovation hubs to establish strategic partnerships with the global life sciences community. Hosted by EBD Group, it brings together leading innovative enterprises and elites from the life sciences sector worldwide. With an exhibition area of 15,000 square meters, this year’s conference is expected to attract over 12,000 professional attendees and 221 exhibitors, connecting academia, startups, growth-stage biotech companies with pharmaceutical giants and forward-thinking investors.

As a representative company in the AI pharmaceutical field, "MindRank" is committed to...World's Leading AI Pharmaceutical PlatformEmpower innovative drug research and development, and accelerate the availability of better drugs for the public. Currently, driven by an industrial-grade one-stop AI pharmaceutical platform centered on Molecule Pro™, the companyThe first self-developed GLP-1RA small molecule oral drug MDR-001 has entered Phase IIb clinical research, and the new anti-tumor drug MRANK-106 has received FDA clinical approval in the United States, with Phase I clinical research soon to be initiated.In addition, the company has several potential best-in-class or first-in-class projects in the fields of metabolism and oncology at the IND-Enabling stage.

At the same time, "MindRank" independently developedAI-empowered molecular glue rational design platform and ADME/T property prediction software,Has demonstrated strong potential in multiple internal and publicly-listed pharmaceutical company collaboration projects, significantly accelerating the R&D process of multimodal drugs such as small molecules, molecular glues, and PROTACs.

MindRank sincerely invites global partners to visit and exchange ideas. If you would like to learn more about the company's innovative pipeline and business development, please feel free to contact us via the PartneringONE® collaboration system or email bd@mindrank.ai. We look forward to expanding new collaborations and partnerships at BIO-Europe Spring.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby enabling more diseases to be treatable and allowing more lives to regain health.

The company owns a self-developed, world-leading industrial-grade one-stop AI-driven innovative drug R&D platform, including PharmKG™, a knowledge graph-based data mining platform, Molecule Dance™, a protein dynamics simulation and structure prediction platform, and Molecule Pro™, a one-stop AI drug design platform. The company’s AI pharmaceutical solutions were recognized by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most significant AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was named one of "China's Most Socially Impactful Startups" on Fortune magazine’s IMPACT list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai